IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. — IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company, announced that on October 29, 2026, the Compensation Committee of its Board of Directors granted non-qualified stock options to purchase a total of 99,600 shares of the company's common stock to four newly hired employees. The grant was made under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award Plan (2023 Inducement Plan), aligning with Nasdaq Listing Rule 5635(c)(4).
The 2023 Inducement Plan is designed exclusively for the issuance of equity awards to individuals who were not previously employees of IDEAYA or who have experienced a bona fide period of non-employment. This serves as a material inducement for their entry into employment with the company, in accordance with Nasdaq regulations.
The stock options have an exercise price of $32.89 per share, which matches the closing price of IDEAYA's common stock on The Nasdaq Global Select Market on the date of the grant. These options have a 10-year term and will vest over a period of four years. Specifically, 25% of the options will vest on the first anniversary of the vesting commencement date, with the remaining 75% vesting in equal monthly installments over the subsequent three years, contingent on the employees' continued service to IDEAYA.
IDEAYA Biosciences focuses on the discovery, development, and commercialization of transformative therapies for cancer, employing a comprehensive approach that combines small-molecule drug discovery, structural biology, and bioinformatics. The company aims to develop tailored, potentially first-in-class targeted therapies aligned to genetic drivers of disease, with a pipeline centered on synthetic lethality and antibody-drug conjugates for molecularly defined solid tumor indications.
For investor inquiries, IDEAYA Biosciences can be contacted through Joshua Bleharski, Ph.D., Chief Financial Officer, at investor@ideayabio.com.